全文获取类型
收费全文 | 2951篇 |
免费 | 119篇 |
国内免费 | 51篇 |
专业分类
耳鼻咽喉 | 68篇 |
儿科学 | 71篇 |
妇产科学 | 58篇 |
基础医学 | 214篇 |
口腔科学 | 35篇 |
临床医学 | 338篇 |
内科学 | 557篇 |
皮肤病学 | 45篇 |
神经病学 | 106篇 |
特种医学 | 302篇 |
外科学 | 305篇 |
综合类 | 314篇 |
一般理论 | 1篇 |
预防医学 | 216篇 |
眼科学 | 33篇 |
药学 | 225篇 |
3篇 | |
中国医学 | 99篇 |
肿瘤学 | 131篇 |
出版年
2023年 | 15篇 |
2022年 | 30篇 |
2021年 | 47篇 |
2020年 | 47篇 |
2019年 | 36篇 |
2018年 | 39篇 |
2017年 | 40篇 |
2016年 | 39篇 |
2015年 | 54篇 |
2014年 | 81篇 |
2013年 | 104篇 |
2012年 | 170篇 |
2011年 | 138篇 |
2010年 | 114篇 |
2009年 | 118篇 |
2008年 | 182篇 |
2007年 | 184篇 |
2006年 | 167篇 |
2005年 | 139篇 |
2004年 | 90篇 |
2003年 | 88篇 |
2002年 | 58篇 |
2001年 | 67篇 |
2000年 | 63篇 |
1999年 | 50篇 |
1998年 | 40篇 |
1997年 | 47篇 |
1996年 | 52篇 |
1995年 | 39篇 |
1994年 | 41篇 |
1993年 | 33篇 |
1992年 | 12篇 |
1991年 | 23篇 |
1990年 | 24篇 |
1989年 | 20篇 |
1988年 | 25篇 |
1987年 | 25篇 |
1986年 | 11篇 |
1985年 | 28篇 |
1984年 | 23篇 |
1983年 | 12篇 |
1980年 | 13篇 |
1977年 | 9篇 |
1959年 | 41篇 |
1958年 | 66篇 |
1957年 | 75篇 |
1956年 | 73篇 |
1955年 | 83篇 |
1954年 | 51篇 |
1948年 | 11篇 |
排序方式: 共有3121条查询结果,搜索用时 140 毫秒
61.
目的探讨尿微量白蛋白(MA)、尿α1-微球蛋白(α1-MG)、尿β2-微球蛋白(β2-MG)及血清β2-微球蛋白(β2-MG)在糖尿病肾病早期诊断中的意义。方法收集67例2型糖尿病患者和82名正常健康人的血清及尿液,分别利用化学发光法检测血清β2-MG、放射免疫法测定尿β2-MG及散射速率比浊法测定尿MA和尿α1-MG水平。结果与正常对照组相比,糖尿病组4组特定蛋白水平明显升高,结果有显著性差异(P均<0.05);此4组蛋白在正常对照组测得的结果无一例阳性,但在糖尿病组的阳性率分别为32.8%、47.8%、35.8%、34.3%;实验还发现随着病程的延长,糖尿病组4组蛋白的阳性率也相应升高(P<0.05)。结论测定尿液中MA、α1-MG、β2-MG及血清β2-MG水平对糖尿病肾病的早期诊断具有一定意义,能够帮助患者及早发现病情,减少疾病迁延。 相似文献
62.
目的研究血小板参数在糖尿病(DM)及 DM合并高血压(HBP)病人中的变化及临床意义。方法收集 2018年 10月至 2019年 8月在武汉大学人民医院确诊为 2型糖尿病(T2DM)的病人 113例,将其作为 DM组; T2DM合并 HBP病人 157例,作为 DM合并 HBP组,并按照血压水平将其分为 HBPⅠ、Ⅱ、Ⅲ级三个亚组;检测并分析两组的空腹血糖(FPG)、糖化血红蛋白(HbA1c)、血小板计数(PLT)、血小板压积(PCT)、平均血小板容积(MPV)、血小板分布宽度(PDW)及大血小板比率(P?LCR)以及通过受试者工作特征(ROC)曲线比较 PLT、MPV、PDW、P?LCR、HbA1c对 DM合并 HBP的诊断价值;并探究 DM合并不同,严重程度 HBP病人以上指标的变化趋势。结果 DM合并 HBP组的 HbA1c[8.90(7.33,10.90)%比 8.70(6.68,10.48)%]、 PLT[222.00(191.50,268.00)109/L比 206.00(179.50,236.50)109/L]、 MPV[11.10(10.45,11.60)fl比 10.20(9.85,10.60)fl]、 PDW[(13.50±2.27)fl比(11.43±1.04)fl]、 P?LCR[(33.92±7.46)%比(25.94±4.49)%]的水平明显高于 DM组,且差异有统计学意义(P<0.05)。随着 HBP严重程度的升高, FPG、MPV、PDW、P?LCR的水平升高,呈明显的上升趋势。 P?LCR的 ROC曲线下面积(AUC)为 0.812,大于 PLT(AUC为 0.618),MPV(AUC为 0.805)、 PDW(AUC为 0.799)和 HbA1c(AUC为 0.578)对 DM合并 HBP的诊断价值最大。结论血小板参数与 DM合并 HBP的发生关系密切,对于诊断评估 DM合并 HBP有一定的价值。, 相似文献
63.
Manganese G8 dendrimers targeted to oxidation‐specific epitopes: In vivo MR imaging of atherosclerosis
下载免费PDF全文
![点击此处可从《Journal of magnetic resonance imaging : JMRI》网站下载免费的PDF全文](/ch/ext_images/free.gif)
64.
65.
Diego Soto Mesa Mounir Fayad Fayad Laura Pérez Arviza Verónica Del Valle Ruiz Fernando Cosío Carre?o Luis Arguelles Tamargo Manuel Amorín Díaz Sergio Fernández-Pello Montes 《World Journal of Clinical Cases》2015,3(4):360-367
AIM: To evaluate the effects of two different doses of sugammadex after maintenance anesthesia with sevofluorane and remifentanil and deep rocuroniuminduced neuromuscular blockade(NMB).METHODS: Patients between 20 and 65 years of age, with American Society of Anesthesiologists physical status classification Ⅰ-Ⅱ, undergoing gynecological surgery were included in a prospective, comparative and randomized study. NMB was induced with an injection of 0.6 mg/kg of rocuronium followed by continuous infusion of 0.3-0.6 mg/kg per hour to maintain a deep block. Anesthesia was maintained with sevofluorane and remifentanil. Finally, when surgery was finished, a bolus of 2 mg/kg(group A) or 4 mg/kg(group B) of sugammadex was applied when the NMB first response in the train-of-four was reached. The primary clinical endpoint was time to recovery to a train-of-four ratio of 0.9. Other variables recorded were the time until recovery of train-of-four ratio of 0.7, 0.8, hemodynamic variables(arterial blood pressure and heart rate at baseline, starting sugammadex, and minutes 2, 5 and 10) and adverse events were presented after one hour in the post-anesthesia care unit.RESULTS: Thirty-two patients were included in the study: 16 patients in group A and 16 patients in group B. Only 14 patients each group were recorded because arterial pressure values were lost in two patients from each group in minute 10. The two groups were comparable. Median recovery time from starting of sugammadex administration to a train-of-four ratio of 0.9 in group A and B was 129 and 110 s, respectively.The estimated difference in recovery time between groups was 24 s(95%CI: 0 to 45 s, Hodges-Lehmann estimator), entirely within the predefined equivalence interval. Times to recovery to train-of-four ratios of 0.8(group A: 101 s; group B: 82.5 s) and 0.7(group A: 90 s; group B: 65 s) from start of sugammadex administration were not equivalent between groups. There was not a significant variation in the arterial pressure and heart rate values between the two groups and none of the patients showed any clinical evidence of residual or recurrent NMB. CONCLUSION: A dose of 2 mg/kg of sugammadex after continuous rocuronium infusion is enough to reverse the NMB when first response in the Train-OfFour is reached. 相似文献
66.
Prompt initial bone marrow engraftment was observed in 10 lethally irradiated dogs receiving infusions of 9.8 to 30.0 x 109 allogeneic marrow cellsstored at -80 C. in dimethyl sulfoxide. The 3 recipients of bone marrow fromunrelated donors, mismatched by canine histocompatibility testing, subsequently rejected their grafts and died within 16 days with marrow hypoplasia.The 3 dogs with matched unrelated donors and the 4 with matched littermate donors all showed sustained marrow engraftment. Evidence of marrowrepopulation by allogeneic cells was obtained by cytogenetic studies in oneand by change to donor red cell type in 3 instances. Submitted on December 16, 1968 Accepted on January 28, 1969 相似文献
67.
Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen 总被引:1,自引:0,他引:1
We have studied the use of a new preparative regimen for the treatment of patients in remission of acute myeloid leukemia (AML) with autologous bone marrow transplantation. Chemotherapy consisted of busulfan 1 mg/kg every 6 hours for 4 days (total dose, 16 mg/kg) on days -7 through -4 followed by an intravenous infusion over 6 to 10 hours of etoposide 60 mg/kg on day -3. Autologous bone marrow, treated in vitro with 100 micrograms/mL of 4-hydroperoxycyclophosphamide, was infused on day 0. We have treated 58 patients up to the age of 60 years, 32 in first remission, 21 in second or third remission, and 5 with primary refractory AML unresponsive to high-dose Ara-C, but achieving remission with aggressive salvage regimens. Of the first remission patients, there has been 1 treatment related death and 5 relapses. With median follow-up of 22 months, the actuarial relapse rate is 22% +/- 9% and disease-free survival is 76% +/- 9% at 3 years. Patients with favorable French-American-British (FAB) subtypes (M3 or M4 EO) did especially well, with no relapses seen in 15 patients observed for a median of 30 months. Actuarial relapse rate at 3 years was 48% for first remission patients with less favorable FAB subtypes. Of patients in second or third remission, there were 5 treatment related deaths and 4 relapses. With median follow-up of 22 months, the actuarial relapse rate is 25% +/- 11% and disease-free survival is 56% +/- 11% at 3 years. Four of five primary refractory patients died during treatment and 1 remains in remission with short follow-up. These preliminary data are very encouraging and, if confirmed, support the use of autologous purged bone marrow transplantation using aggressive preparative regimens as one approach to improve the outcome of adults with AML. 相似文献
68.
Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid cell-specific monoclonal antibodies 总被引:1,自引:0,他引:1
Second or third chemotherapy-induced remissions in acute myelogenous leukemia (AML) are limited by early relapse of the leukemia. We developed monoclonal antibodies (MoAbs) that are cytotoxic to myeloid leukemia cells to treat bone marrow from these patients ex vivo for autologous transplantation. In this pilot study, bone marrow was harvested from ten patients with AML in remission, treated with one or two complement-fixing MoAbs, PM-81 and AML-2-23, which react with myeloid differentiation antigens, incubated with rabbit complement, and cryopreserved. These MoAbs were chosen because they have broad reactivity with AML cells but not with pluripotent progenitor cells. At the time of transplant, 6 patients were in second complete remission, 1 each was in third complete or partial remission, and 2 were in early first relapse. The patients were treated with cyclophosphamide (60 mg/kg a day for 2 days) and total body irradiation (200 cGy twice a day for 3 days) and given infusions of MoAb-treated bone marrow. Full bone marrow reconstitution was observed in eight patients; two patients did not recover platelets. Seven of the ten patients are surviving and disease-free at 21.0, 15.0, 13.0, 10.0, 6.0, 3.0, and 2.0 months posttransplant. Treating bone marrow with MoAbs to myeloid differentiation antigens does not interfere with pluripotential stem cell engraftment. Longer follow-up and a controlled study are necessary to prove that the apparent efficacy of this therapeutic approach in some patients is attributable to MoAb-mediated killing of leukemia cells. 相似文献
69.
70.
EDUARDO ARANA‐RUEDA M.D. Ph.D. ALONSO PEDROTE M.D. Ph.D. LORENA GARCÍA‐RIESCO M.D. ALVARO ARCE‐LEÓN M.D. FEDERICO GÓMEZ‐PULIDO M.D. JUAN‐MANUEL DURÁN‐GUERRERO M.D. AGUSTÍN FERNÁNDEZ‐CISNAL M.D. MANUEL FRUTOS‐LÓPEZ M.D. JUAN‐ANTONIO SÁNCHEZ‐BROTONS M.D. 《Pacing and clinical electrophysiology : PACE》2015,38(2):216-224